Amble Review

Amble — Provider Profile

Overview

Amble is a telehealth platform offering compounded GLP-1 medications with a commitment-tier pricing model built around predictability. The headline feature is flat-rate pricing across all dose levels — patients pay the same monthly rate regardless of where they are in titration — combined with price breaks that deepen as commitment length increases, from one-month to twelve-month plans.

Operating in all 50 states (with some state restrictions on compounded tirzepatide), Amble pairs GLP-1 prescriptions with unlimited 24/7 support and lifestyle coaching. The platform works through licensed physicians, with certain states requiring a video or phone visit before approval.

April 2026 context: Amble prescribes compounded semaglutide and compounded tirzepatide. Compounded GLP-1s are not FDA-approved — they are prepared by state-licensed 503A pharmacies under individual patient prescriptions. The FDA has taken enforcement action against certain compounders and continues to pressure the sector. Patients choosing a compounded pathway should weigh this regulatory context carefully.

Medications Offered

• Compounded semaglutide injectable — Not FDA-approved; compounded at state-licensed 503A pharmacies
• Compounded tirzepatide injectable — Not FDA-approved; available in approximately 45 states
• FDA-approved options — Available situationally for patients who prefer or qualify for brand-name medications
• Additional injectables: NAD+, Sermorelin, Tesamorelin, Glutathione, Lipo-B, Lipo-C

Pricing

All plans include medication, supplies, shipping, and ongoing clinical monitoring. Pricing is flat across all dose levels within the initial period — meaning a patient titrating from a starting dose to a therapeutic dose does not pay more as the dose increases.

One important caveat: Amble's pricing may increase from the base rate after four months at higher doses. This partially limits the flat-rate claim — patients on long-term high-dose therapy should confirm their actual ongoing rate before enrolling.

The 12-month plan at $135/mo is among the most competitive ongoing rates in the compounded GLP-1 market for patients who know they will be on treatment for a full year.

States Served

All 50 states. Compounded tirzepatide is available in approximately 45 states — specific state restrictions apply. Contact Amble to confirm tirzepatide availability in your state before enrolling.

Video or phone consultation required before approval in: New Mexico, Kansas, West Virginia, Louisiana, Mississippi.

Insurance

• Insurance: Not accepted
• HSA/FSA: Accepted on 3-month, 6-month, and 12-month plans (not on the 1-month plan)

Consultation Process

1. Complete an online health assessment
2. A licensed physician reviews your submission
3. Certain states require a video or phone visit before treatment approval
4. Treatment plan provided via patient portal
5. Medication ships with free expedited delivery

Ongoing: unlimited 24/7 support and lifestyle coaching throughout treatment.

Pros

• Flat-rate pricing removes dose-escalation cost uncertainty
• 12-month plan at $135/mo is highly competitive for long-term patients
• Four commitment tiers give flexibility (1, 3, 6, 12 months)
• Unlimited 24/7 support included
• Free expedited delivery
• Lifestyle coaching integrated into the program
• FDA-approved pathway available for patients who qualify
• HSA/FSA accepted on longer plans

Cons

• Pricing may increase after four months at higher doses — the flat-rate claim has limits
• Compounded tirzepatide not available in all 50 states (~45 states)
• No insurance accepted
• Compounded GLP-1s are not FDA-approved; face active FDA enforcement pressure
• Some states require video/phone visit before approval (may add friction for fully async-seeking patients)
• Auto-subscription model — cancellation terms should be confirmed before enrolling

Best For

Patients who are committed to a longer treatment course and want pricing certainty. The flat-rate model addresses a real problem — most compounded GLP-1 providers charge more at higher doses, which is when patients actually need more medication. At $135/mo on a 12-month plan, Amble is competitive for patients who have already decided on a compounded GLP-1 pathway and want to lock in a predictable rate.

Not ideal for: Patients who are still deciding whether GLP-1 therapy is right for them (the 1-month option is available but not the cheapest single-month option on the market), or patients who prefer brand-name medications as their primary option.

Editorial Verdict

Amble's pricing architecture is patient-friendly in a market where most providers obscure total cost. The tiered commitment pricing is straightforward, and the flat-rate-across-dose-levels model removes a common source of mid-treatment sticker shock. For a patient who knows they'll need a full year of therapy, $135/mo all-inclusive is a strong rate.

"Flat rate" technically applies within the initial period — pricing may increase after four months at higher doses. Patients should get written confirmation of their long-term rate before choosing Amble specifically for its pricing predictability.

The compounded medications carry the same regulatory uncertainty as every other non-FDA-approved option in this space. The FDA is actively pressuring compounders as of April 2026, and supply or legal conditions can change. Amble's offer of an FDA-approved pathway is a useful backup, though it comes at significantly higher cost.

Bottom line as of April 2026: Amble earns consideration for patients who want long-term pricing predictability and plan to commit to treatment for six months or more. Confirm the fine print on the higher-dose rate increase before enrolling.

Related Content

• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• GLP-1 Compounding Pharmacies: What Patients Need to Know — Full regulatory context
• GLP-1 Cost & Insurance FAQ — What you'll actually pay